Founded in 2004, Araclon Biotech has developed into a large research project, focused on the diagnosis and treatment of Alzheimer’s disease. The project, which began in the University of Zaragoza, has been led from the beginning by Dr. D. Manuel Sarasa, chief scientific officer and CEO of Araclon Biotech.

This project has led to a series of patents being licensed by the company, in order to continue developing.

At the end of 2006, the company, with the help of several investors, increased its number of research projects, creating a new organization, clarifying its business and research strategy, and planning the construction of its own R+D laboratory.

In 2008, Araclon gained support from the Government of La Rioja, allowing it to begin a new line of research in its CIBIR facilities.

In 2009, Araclon obtained its first European patent for a vaccine against Alzheimer’s disease.

2010 saw the first regulatory preclinical test of its immunotherapy against Alzheimer’s disease take place.
In 2012, Grifols, a global leader in plasma-derived biological drugs, acquires a 51% stake in Araclon Biotech and ensures the viability and continuity of its projects. This participation as a main shareholder, allows Grifols to promote a research strategy in Alzheimer, comprehensively addressing this degenerative disease: early diagnosis, new treatments with plasma derivatives which may slow disease evolution and development of a vaccine as a prophylactic measure.